1. Home
  2. ENTX vs INVE Comparison

ENTX vs INVE Comparison

Compare ENTX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • INVE
  • Stock Information
  • Founded
  • ENTX 2010
  • INVE 1990
  • Country
  • ENTX Israel
  • INVE United States
  • Employees
  • ENTX N/A
  • INVE N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • INVE Computer peripheral equipment
  • Sector
  • ENTX Health Care
  • INVE Technology
  • Exchange
  • ENTX Nasdaq
  • INVE Nasdaq
  • Market Cap
  • ENTX 90.2M
  • INVE 86.5M
  • IPO Year
  • ENTX 2018
  • INVE 1997
  • Fundamental
  • Price
  • ENTX $2.59
  • INVE $3.55
  • Analyst Decision
  • ENTX Strong Buy
  • INVE Strong Buy
  • Analyst Count
  • ENTX 1
  • INVE 2
  • Target Price
  • ENTX $10.00
  • INVE $7.25
  • AVG Volume (30 Days)
  • ENTX 82.5K
  • INVE 39.3K
  • Earning Date
  • ENTX 03-07-2025
  • INVE 03-11-2025
  • Dividend Yield
  • ENTX N/A
  • INVE N/A
  • EPS Growth
  • ENTX N/A
  • INVE N/A
  • EPS
  • ENTX N/A
  • INVE 3.10
  • Revenue
  • ENTX $99,000.00
  • INVE $104,217,000.00
  • Revenue This Year
  • ENTX N/A
  • INVE N/A
  • Revenue Next Year
  • ENTX N/A
  • INVE N/A
  • P/E Ratio
  • ENTX N/A
  • INVE $1.16
  • Revenue Growth
  • ENTX 607.14
  • INVE 70.57
  • 52 Week Low
  • ENTX $0.71
  • INVE $2.95
  • 52 Week High
  • ENTX $3.35
  • INVE $9.24
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 61.93
  • INVE 43.25
  • Support Level
  • ENTX $2.00
  • INVE $3.50
  • Resistance Level
  • ENTX $2.62
  • INVE $3.82
  • Average True Range (ATR)
  • ENTX 0.18
  • INVE 0.18
  • MACD
  • ENTX 0.01
  • INVE -0.01
  • Stochastic Oscillator
  • ENTX 96.77
  • INVE 21.82

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

Share on Social Networks: